NCT00339144View on ClinicalTrials.gov

Study of Dasatinib (BMS-354825) in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Tumors
Interventions
DRUG

Dasatinib

tablets, Oral, 100 mg, once daily for 4 weeks

DRUG

Dasatinib

tablets, Oral, 150 mg, once daily, 4 weeks

DRUG

Dasatinib

tablets, Oral, 200 mg, once daily for 4 weeks

Trial Locations (2)

589-0014

Local Institution, Sayama

135-0063

Local Institution, Koto-Ku

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY